Although single-agent immune checkpoint inhibitor (ICI) therapy with monoclonal antibodies targeting CTLA-4 and PD-1 has been the standard of care for patients with metastatic melanoma, the majority of patients did not experience long-term benefits from ICI monotherapy. This evidence concerns the gene CTLA4 and metastatic melanoma.